Squarepoint
PROK icon

Squarepoint’s ProKidney PROK Stock Holding History

Squarepoint’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$378K Sell
211,107
-140,314
-40% -$298K ﹤0.01% 3535
2025
Q4 		$787K Buy
351,421
+6,845
+2% +$18K ﹤0.01% 2820
2025
Q3 		$834K Buy
+344,576
New +$917K ﹤0.01% 2833
2024
Q4 		– Sell
-17,976
Closed -$34.5K – 5406
2024
Q3 		$34.5K Buy
17,976
+1,599
+10% +$3.63K ﹤0.01% 3999
2024
Q2 		$40.3K Sell
16,377
-21,373
-57% -$57.4K ﹤0.01% 3928
2024
Q1 		$61.9K Sell
37,750
-169,932
-82% -$250K ﹤0.01% 3858
2023
Q4 		$370K Buy
+207,682
New +$445K ﹤0.01% 3222
2023
Q2 		– Sell
-25,883
Closed -$293K – 3913
2023
Q1 		$293K Buy
+25,883
New +$275K ﹤0.01% 2586
2021
Q3 		– Sell
-350,000
Closed -$3.54M – 3324
2021
Q2 		$3.54M Buy
+350,000
New +$3.54M 0.01% 889

Other funds holding PROK

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Squarepoint's PROK Position: Q1 2026 in Review

Squarepoint reduced its ProKidney (PROK) stake by 40% in Q1 2026, selling an estimated $298K and leaving 211,107 shares worth $378K. The position accounts for ﹤0.01% of the portfolio, ranked #3535.

Squarepoint first reported a position in PROK in Q2 2021 and has held it in 9 quarters since. The position peaked at $3.54M in Q2 2021. 71 funds tracked by Wall St. Rank hold PROK as of Q1 2026.

  • Squarepoint held 211,107 shares of ProKidney worth $378K as of Q1 2026.
  • Squarepoint sold 140,314 ProKidney shares in Q1 2026, an estimated $298K.
  • ProKidney made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3535 holding.
  • Squarepoint first reported a position in ProKidney in Q2 2021 and has held it in 9 quarters since.
  • Squarepoint's ProKidney position peaked at $3.54M in Q2 2021.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.